Susanne Bejerot, Sofia Sigra Stein, Elisabet Welin, Daniel Eklund, Ulrika Hylén, Mats B. Humble, Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder: Two open-label pilot studies on treatment-resistant patients. Journal of Psychiatric Research. Volume 158, 2023, Pages 319-329, https://doi.org/10.1016/j.jpsychires.2022.12.0
-
Treatment-resistant schizophrenia benefitted from add-on treatment with rituximab.
-
Patients with schizophrenia, but not those with OCD, were much improved.
-
A ≥ 40% decrease of symptoms was seen in 7/9 patients with schizophrenia week 12.
-
Disability was diminished by 64% in patients with schizophrenia week 12.
-
Rituximab was well tolerated, and antipsychotic-related side effects decreased.